Dr. Joe W. Gray, a physicist and an engineer by training, holds positions as Professor and Gordon Moore Endowed Chair, Biomedical Engineering Department Vice Chair; Director, Center for Spatial Systems Biomedicine (OCSSB); and Associate Director for Biophysical Oncology, Knight Cancer Institute at the Oregon Health & Science University. He is also Emeritus Professor, University of California, San Francisco; and Senior Scientist, Lawrence Berkeley National Laboratory.
He was a Staff Scientist in the Biomedical Sciences Division of the Lawrence Livermore National Laboratory (1972-1991), Professor of Laboratory Medicine at the University of California, San Francisco (1991-2011), and Associate Laboratory Director for Biosciences and Life Sciences Division Director at the Lawrence Berkeley National Laboratory (2003-2011).
He is Principal Investigator of the National Cancer Institute / Research Center for Cancer Systems Biology Consortium (CSBC), "Measuring, Modeling and Controlling Heterogeneity" (M2CH) that is aimed at developing a systems level understanding of how intrinsic and extrinsic factors work together to enable triple-negative breast cancer to escape therapeutic control in order to devise robust control strategies; PI of a National Institutes of Health program to contribute to further development of the NIH Library of Integrated Network-based Cellular Signatures program (LINCS) to develop a dataset and computational strategy to elucidate how microenvironmental signals affect cell intrinsic intracellular transcriptional- and protein-defined molecular networks to generate experimentally durable therapies for patients; PI of a Prospect Creek Foundation study "Serial Measurement of Molecular and Architectural Responses to Therapy" (SMMART) to provide a transformative approach to cancer treatment that focuses on each person who faces cancer to create more effective, durable therapies for treatment of prostate cancer, pancreatic cancer and leukemia; PI of a Brenden Colson Center for Pancreatic Health project that provides support for a broad-based, team approach to finding causes, early detection and improvement of clinical care for pancreatic diseases including pancreatitis and pancreatic cancer; and PI of a Susan G. Komen project to identify the mechanisms by which ERBB2+ breast cancer cells escape inhibition by ERRB2-targeted therapies.
Dr. Gray's work is described in over 400 publications and in 80 US patents. He is a Fellow of the American Association for the Advancement of Science and the American Institute for Medical and Biological Engineering; an elected a member of the Institute of Medicine of the National Academy of Sciences; a member of the National Institutes of Health, Frederick Advisory Committee to the Director of the National Cancer Institute; a Fellow of the American Association of Cancer Research Academy; and United States Councilor to the Radiation Effects Research Foundation (RERF), Hiroshima, JapanRead more
- "Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting." Cell Reports In: , Vol. 26, No. 3, 15.01.2019, p. 608-623.e6.
- "Implementing a comprehensive translational oncology platform : From molecular testing to actionability." Journal of Translational Medicine In: , Vol. 16, No. 1, 358, 14.12.2018.
- "Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer." Nature Communications In: , Vol. 9, No. 1, 3815, 01.12.2018.
- "Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution." Cell Reports In: , Vol. 25, No. 4, 23.10.2018, p. 871-883.
- "Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival." Science Advances In: , Vol. 4, No. 9, eaat7828, 12.09.2018.
- "Molecular Cytogenetics Guides Massively Parallel Sequencing of a Radiation-Induced Chromosome Translocation in Human Cells." Radiation Research In: , Vol. 190, No. 1, 01.07.2018, p. 88-97.
- "Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment." PLoS One In: , Vol. 13, No. 6, e0198141, 01.06.2018.
- "CCR5 Governs DNA damage repair and breast cancer stem cell expansion." Cancer Research In: , Vol. 78, No. 7, 01.04.2018, p. 1657-1671.
- "MHC class I loaded ligands from breast cancer cell lines : A potential HLA-I-typed antigen collection." Journal of Proteomics In: , Vol. 176, 30.03.2018, p. 13-23.
- "Erratum : Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes (Nature communications (2017) 8 1 (1231))." Nature communications In: , Vol. 9, No. 1, 05.02.2018.
- "Simultaneous Multicolor Single-Molecule Tracking with Single-Laser Excitation via Spectral Imaging." Biophysical Journal In: , Vol. 114, No. 2, 23.01.2018, p. 301-310.
- "Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes." Cell Systems In: , 01.01.2018.
- "SHIFT : Speedy histopathological-To-immunofluorescent translation of whole slide images using conditional generative adversarial networks." Medical Imaging 2018: Digital Pathology. Vol. 10581 SPIE, 2018. 1058105.
- "Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution." Scientific Reports In: , Vol. 7, No. 1, 16459, 01.12.2017.
- "Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer." Molecular Cancer Therapeutics In: , Vol. 16, No. 12, 01.12.2017, p. 2892-2901.
- "Combating subclonal evolution of resistant cancer phenotypes." Nature Communications In: , Vol. 8, No. 1, 1231, 01.12.2017.
- "Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics." Scientific data In: , Vol. 4, 170166, 07.11.2017.
- "Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound." Cell Reports In: , Vol. 21, No. 2, 10.10.2017, p. 533-545.
- "Correction : Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer (PLoS ONE (2015) 10:7 (e0133219) DOI: 10.1371/journal.pone.0133219)." PLoS One In: , Vol. 12, No. 10, e0186551, 01.10.2017.
- "Deep learning based Nucleus Classification in pancreas histological images." 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society: Smarter Technology for a Healthier World, EMBC 2017 - Proceedings. Institute of Electrical and Electronics Engineers Inc., 2017. p. 672-675 8036914.
- "Multiplexed immunohistochemistry image analysis using sparse coding." 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society: Smarter Technology for a Healthier World, EMBC 2017 - Proceedings. Institute of Electrical and Electronics Engineers Inc., 2017. p. 4046-4049 8037744.
- "HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2 breast cancer." Clinical Cancer Research In: , Vol. 23, No. 17, 01.09.2017, p. 5123-5134.
- "Breast cancer histopathology image analysis pipeline for tumor purity estimation." 2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017. IEEE Computer Society, 2017. p. 1137-1140 7950717.
- "Quantitating morphological changes in biological samples during scanning electron microscopy sample preparation with correlative super-resolution microscopy." PLoS One In: , Vol. 12, No. 5, e0176839, 01.05.2017.
- "Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes." Genome Medicine In: , Vol. 9, No. 1, 40, 26.04.2017.
- "Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis." Cell Reports In: , Vol. 19, No. 1, 04.04.2017, p. 203-217.
- "Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform." Molecular Cancer Therapeutics In: , Vol. 16, No. 4, 01.04.2017, p. 763-772.
- "Erratum to : "Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer", [Breast Cancer Research, 19, (2017) (17)] DOI: 10.1186/s13058-017-0809-6." Breast Cancer Research In: , Vol. 19, No. 1, 17, 09.02.2017.
- "Circulating-tumor DNA as an early detection and diagnostic tool." Current Opinion in Genetics and Development In: , Vol. 42, 01.02.2017, p. 14-21.
- "Epigenomic inactivation of RasGAPs activates RAS signaling in a subset of luminal B breast cancers." Cancer Discovery In: , Vol. 7, No. 2, 01.02.2017, p. 131-133.